Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| V116517 - 50 mg | Experimental | V116517 50-mg tablets |
|
| V116517 - 30 mg | Experimental | V116517 30-mg tablets |
|
| Naproxen 500 mg | Active Comparator | Naproxen 500-mg capsules |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| V116517 50-mg tablets | Drug | Taken orally twice daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Western Ontario and McMaster OA Index (WOMAC) Pain Score | Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| WOMAC Physical Function Score | Week 4 | |
| WOMAC Stiffness Score | Week 4 | |
| Modified Brief Pain Inventory - Short Form (mBPI-SF) Severity of Pain and Interference of Pain |
Not provided
Key Inclusion Criteria:
Subjects with moderate pain due to OA of the knee as their primary pain condition.
Subjects with diagnostic criteria for primary pain condition (American college of Rheumatology [ACR] clinical and radiographic criteria):
Key Exclusion Criteria:
Subjects with chronic pain conditions other than OA of the knee as their predominant pain condition, including gout, pseudo gout, psoriatic arthritis, active Lyme disease, rheumatoid arthritis or any other inflammatory arthritis, fibromyalgia, neuropathic pain conditions, bursitis, or acute injury or signs of active infection in the target pain area.
Subjects who cannot or will not agree to stop all concomitant analgesic medications, apart from specified protocol supplemental analgesic medications.
Subjects with history of seizures within the past 5 years.
Subjects who use opioids more than 4 days per week.
Pain-condition-specific exclusions:
Subjects who have had arthroscopy on either knee or hip within 6 months of entering the study, or open surgery on either knee or hip within 12 months of entering the study.
Active-comparator-related exclusions:
Other protocol specific inclusion/exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Genova Clinical Research, Inc. | Tucson | Arizona | 85704 | United States | ||
| Orthopedic Research Institute |
Not provided
Not provided
Not provided
Not provided
Not provided
| V116517 30-mg tablets |
| Drug |
Taken orally twice daily |
|
| Naproxen 500-mg capsules | Drug | Taken orally twice daily |
|
| Placebo | Drug | Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily |
|
| Week 4 |
| Patient Global Impression of Change (PGIC) | Week 4 |
| Supplemental Analgesic Medication Use | Over 4 weeks |
| Boynton Beach |
| Florida |
| 33472 |
| United States |
| Avail Clinical Research, LLC | DeLand | Florida | 32720 | United States |
| Westside Center for Clinical Research | Jacksonville | Florida | 32205 | United States |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | United States |
| Health Awareness, Inc. | Jupiter | Florida | 33458 | United States |
| Compass Research, LLC | Orlando | Florida | 32806 | United States |
| Compass Research East, LLC | Oviedo | Florida | 32765 | United States |
| Northwest Indiana Center for Clinical Research | Valparaiso | Indiana | 46383 | United States |
| Analgesic Solutions | Natick | Massachusetts | 01760 | United States |
| Great Lakes Research Group, Inc. | Bay City | Michigan | 48706 | United States |
| PMG Research of Charlotte, LLC. | Charlotte | North Carolina | 28209 | United States |
| PMG Research of Raleigh, LLC | Raleigh | North Carolina | 27609 | United States |
| Wake Research Associates, LLC | Raleigh | North Carolina | 27612 | United States |
| LION Research | Norman | Oklahoma | 73069 | United States |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | United States |
| Clinical Research Center of Reading, LLP | Wyomissing | Pennsylvania | 19610 | United States |
| PMG Research of Bristol | Bristol | Tennessee | 37620 | United States |
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| D010146 | Pain |
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000595012 | 4-(3-chloro-5-(1,2-dihydroxyethyl)-2-pyridyl)-N-(5-(trifluoromethyl)-2-pyridyl)-3,6-dihydro-2H-pyridine-1-carboxamide |
| D009288 | Naproxen |
| ID | Term |
|---|---|
| D009280 | Naphthaleneacetic Acids |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
Not provided
Not provided